Shares of Viatris Inc. VTRS advanced 1.19% to $11.06 Thursday, on what proved to be an all-around dismal trading session for ...

Viatris is no longer speaking about divestitures, so we may conclude that management are content with what's been achieved already and are looking to augment its products and pipeline with M&A ...

Viatris' earnings beat was driven by effective cost management. For fiscal 2024, analysts anticipate Viatris to report an EPS of $2.68, down 8.5% from $2.93 in fiscal 2023 .

This was the stock's second consecutive day of losses.

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other stocks. Wall Street's main indices all finished in the green territory on Wednesday ...

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer patient ...